These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 29667815)
1. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor. Qin X; Fang L; Zhao J; Gou S Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815 [TBL] [Abstract][Full Text] [Related]
2. Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity. Ouellette V; Côté MF; Gaudreault RC; Tajmir-Riahi HA; Bérubé G Eur J Med Chem; 2019 Oct; 179():660-666. PubMed ID: 31279298 [TBL] [Abstract][Full Text] [Related]
3. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon. Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526 [TBL] [Abstract][Full Text] [Related]
4. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity. Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585 [TBL] [Abstract][Full Text] [Related]
5. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo. Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239 [TBL] [Abstract][Full Text] [Related]
6. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug. Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261 [TBL] [Abstract][Full Text] [Related]
7. Tailoring Platinum(IV) Amphiphiles for Self-Targeting All-in-One Assemblies as Precise Multimodal Theranostic Nanomedicine. He S; Li C; Zhang Q; Ding J; Liang XJ; Chen X; Xiao H; Chen X; Zhou D; Huang Y ACS Nano; 2018 Jul; 12(7):7272-7281. PubMed ID: 29906087 [TBL] [Abstract][Full Text] [Related]
8. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087 [TBL] [Abstract][Full Text] [Related]
9. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1. Xu Z; Hu W; Wang Z; Gou S Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068 [TBL] [Abstract][Full Text] [Related]
11. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy. Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698 [TBL] [Abstract][Full Text] [Related]
12. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer. Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125 [TBL] [Abstract][Full Text] [Related]
13. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer. Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396 [TBL] [Abstract][Full Text] [Related]
14. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437 [TBL] [Abstract][Full Text] [Related]
15. 7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer. Kandil S; Westwell AD; McGuigan C Bioorg Med Chem Lett; 2016 Apr; 26(8):2000-4. PubMed ID: 26965862 [TBL] [Abstract][Full Text] [Related]
16. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment. Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224 [TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents. Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001 [TBL] [Abstract][Full Text] [Related]
18. Alternative mechanism of action of the DNP Pt Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020 [TBL] [Abstract][Full Text] [Related]
19. Cis,cis,trans-[Pt Ravera M; Gabano E; Zanellato I; Rangone B; Perin E; Ferrari B; Bottone MG; Osella D Dalton Trans; 2021 Mar; 50(9):3161-3177. PubMed ID: 33595015 [TBL] [Abstract][Full Text] [Related]
20. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells. Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]